78 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
17 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Jan 2027
Next term end
43
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2037 · High confidence
Also notable
Ends Nov 2034 · High confidence
Also notable
Ends Dec 2027 · High confidence
Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer
US 9,943,505
Cited by 49 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2037.
Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators
US 10,047,082
Cited by 57 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Fused Ring Azadecalin Glucocorticoid Receptor Modulators
US 7,928,237
The most cited patent in this portfolio, cited by 106 later US patents, top 10% of utility patents granted in 2011 in our data. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 27, 2026 · next Dec 18
- 1 fee due Mar 19, 2027The maintenance fee for Polymorphs of Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators (US 11,760,731) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 2 fees due Apr 17 to 22, 2027 · next Apr 17
- 1 fee due May 28, 2027The maintenance fee for Method of Preparing Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators (US 11,827,608) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 2 fees due Aug 6 to 20, 2027 · next Aug 6
- 1 fee due Sep 12, 2027The maintenance fee for Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound (US 11,925,626) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 3 fees due Oct 2 to 30, 2027 · next Oct 2
- 1 fee due Nov 12, 2027The maintenance fee for Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer (US 10,646,474) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 19, 2026
- 1 term has ended since Aug 19, 2026
What they patent
The 5 largest of its 43 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,450,379 | Methods for treating migraine In force · High confidence | In force | High confidence | |
| US 7,928,237 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators In force · High confidence | In force | High confidence | |
| US 8,097,606 | Antiglucocorticoids for the Treatment of Catatonia In force · High confidence | In force | High confidence | |
| US 8,598,149 | Optimizing Mifepristone Levels in Plasma Serum of Patients Suffering from Mental Disorders Treatable with Glucocorticoid Receptor Antagonists In force · High confidence | In force | High confidence | |
| US 11,103,514 | Treatment of Muscular Dystrophy In force · High confidence | In force | High confidence | |
| US 8,461,172 | Solid Forms and Process for Preparing In force · High confidence | In force | High confidence | |
| US 8,598,154 | Pyridyl-Amine Fused Azadecalin Modulators In force · High confidence | In force | High confidence | |
| US 8,685,973 | Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators In force · High confidence | In force | High confidence | |
| US 8,829,024 | Combination Steroid and Glucocorticoid Receptor Antagonist Therapy In force · High confidence | In force | High confidence | |
| US 10,047,082 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force · High confidence | In force | High confidence |
Also on record, not counted in the 78: 8 patents ended · 40 applications pending · 10 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.